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PURPOSE. Reticular pseudodrusen (RPD) are considered to be a distinct feature in AMD.
Population studies have studied the epidemiology of RPD using standard color fundus
photographs (CFP). However, recent studies have shown that RPD are better imaged using
near-infrared (NIR) imaging. We studied the epidemiology of RPD in a large population-based
study using NIR and CFP.
METHODS. Participants aged 65þ years from the Rotterdam Study underwent ophthalmo-
logic examination including NIR and CFP. Both images were graded for the presence of
RPD and soft indistinct drusen (SID). Associations with demographic and environmental
factors, 26 genetic variants, and total genetic risk score were analyzed using logistic
regression analysis.
RESULTS. Reticular pseudodrusen were detected in 137 (4.9%) of 2774 study participants; of
these, 92.7% were detected with NIR imaging and 38% on CFP. Most eyes with RPD showed
presence of SID, whereas other drusen types coincided less frequently. Reticular
pseudodrusen were significantly associated with age (odds ratio [OR] 1.21, 95% Confidence
Interval [CI] 1.17–1.24) and female sex (OR 2.10, 95% CI 1.41–3.13). Environmental factors
did not show a significant association with RPD. Major AMD risk variants were significantly
associated with RPD and SID; however, ARMS2, C3, and VEGFA were more associated with
RPD (RPD vs. SID P < 0.05). Total genetic risk score did not differ significantly (P ¼ 0.88).
CONCLUSION. Detection of RPD was better with NIR imaging than on CFP in a population-based
setting. Presence of RPD often coincided with presence of SID; however, they showed
quantitative differences in genetic risk profile.
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Reticular pseudodrusen (RPD), also known as subretinaldrusenoid deposits (SDD), are depositions located in the
subretinal space between the outer segments of the photore-
ceptors and the RPE.1–3 Reticular pseudodrusen carry a much
higher risk of developing end-stage AMD than other AMD
lesions, such as soft indistinct drusen (SID).4–7 Reticular
pseudodrusen were first described in 1990 and it was already
then pointed out that RPD are better visualized using blue
reflectance photography than regular color fundus photo-
graphs (CFP).8 Reticular pseudodrusen can also be detected
using other imaging modalities. A comparative study between
various image modalities showed that near-infrared (NIR)
imaging is one of the image modalities that has the highest
sensitivity for RPD detection,9 and that sensitivity of RPD
detected only on CFP can be as low as 36%.10
Several risk factors have been identified for RPD, which
include age, smoking, higher body mass index (BMI), female
predominance, and genetic risk factors, including CFH(Y402H)
and ARMS2(A69S).4,6,7,11–13 Previous studies have shown that
RPD were present in 60% to 90% of patients with late
AMD.14–16 Boddu et al.13 studied risk profiles of RPD versus
large soft drusen in a small clinic-based study. These researchers
could not find many significant differences between these
patient groups; however, individuals with RPD were older and
more often female.
Because the population-based studies on RPD based their
grading solely on CFP, and the clinic-based studies were carried
out only in small groups, risk estimates are likely to be
imprecise.11 Improved detection of RPD in a large population-
based study may provide more accurate prevalence figures, and
could enhance risk profiling for RPD.
In this study, we aimed to investigate the epidemiology of
RPD using CFP and NIR images and compare this with SID in a
large, unselected population. We have chosen to use the term
RPD instead of SDD, because this is more commonly used in
clinical-based articles; however, where RPD is written SDD can
be read.
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METHODS
Study Population
The Rotterdam Study is a prospective population-based cohort
study that focuses on chronic ophthalmologic, neurologic,
cardiovascular, and locomotor diseases in middle-aged and
elderly subjects living in Ommoord, a suburb of Rotterdam.
The aims and design of the Rotterdam Study have been
described elaborately elsewhere.17 In brief, the study started in
1989, and since then, every 2 to 4 years, follow-up
examinations were performed. During these follow-up exam-
inations, new techniques and devices were implied, such as
the Heidelberg Retina Angiograph 2, a scanning laser
ophthalmoscope. The Rotterdam Study was approved by the
Medical Ethics Committee of the Erasmus MC and by the
Ministry of Health, Welfare, and Sport of the Netherlands,
implementing the ‘‘Wet Bevolkingsonderzoek: ERGO (Popula-
tion Studies Act: Rotterdam Study).’’ All participants provided
written informed consent to participate in the study and to
obtain information from their treating physicians.
For the current cross-sectional analysis, we included 3108
participants from the last examination round from two
independent cohorts of the Rotterdam Study: 1542 participants
from the Rotterdam Study I (RS-I), aged 70 years and older, and
1566 participants from the Rotterdam Study II (RS-II), aged 65
years and older. Participants were excluded from the analyses if
they had ungradable CFP (n ¼ 17) or ungradable NIR images
(n ¼ 68). Since the Heidelberg Retina Angiograph 2 was
operational a few weeks after the start of the examination
round, an additional 266 participants were excluded from the
study due to absence of NIR images. From these two cohorts,
2774 participants with gradable CFP and gradable NIR imaging
were eligible for analysis.
Grading of AMD, SID, and RPD
All eligible participants underwent 358 digital CFP of the
macula (Topcon TRC-50EX; Topcon Optical Company, Tokyo,
Japan, with a Sony DXC-950P digital camera, 0.44 megapixel;
Sony Corporation, Tokyo, Japan) after pharmacologic mydria-
sis. Next, NIR images (k ¼ 820 nm) 308 3 308 of the macula,
were taken with a Heidelberg Retina Angiograph 2 (Heidelberg
Engineering, Heidelberg, Germany).
Color fundus photographs were graded for presence of all
AMD-related features according to the Wisconsin Age-Related
Maculopathy Grading18 and Rotterdam classification (for
definition see Table 1), a modified International Classification
System, using the standard grading grid for AMD, equal to the
Early Treatment Diabetic Retinopathy Study grading grid
(central circle 1000 lm, inner circle 3000 lm, and outer circle
6000 lm in diameter).19,20 In short, the Rotterdam classifica-
tion consists of five grades with grade 0 defined as no AMD,
grade 1 as preliminary early AMD, grades 2 and 3 together as
early AMD, and grade 4 as late AMD. Soft indistinct drusen
were defined as yellow lesions with indistinct borders and
‡125 lm in size. These type of soft drusen are associated with
a higher risk of developing advanced AMD compared with soft
distinct drusen.20 Reticular pseudodrusen were defined as
indistinct yellowish lesions interlacing in networks 125 to 250
lm in width.18,19
Near-infrared images of the macula were graded based on
the presence of RPD, detectable as groups of hyporeflectant
lesions against a mildly hyperreflectant background in regular
patterns.9,10,21,22 Because SID and other drusen types are less
visible on NIR imaging, these lesions were not graded on NIR,
only on CFP.
On CFP, RPD and/or SID were graded inside and outside the
standard grading grid. On NIR, RPD was graded if present on
the image, this equals grading inside and outside the grading
grid on CFP.
All images were graded by trained graders, while being
masked for the grading of the other image modality, under the
supervision of senior retinal specialists (PTVMdJ, JRV, CCWK).
Between-grader comparisons were assessed. For drusen
grading on CFP, the weighted j values ranged from 0.60 for
hard drusen to 0.82 for soft distinct drusen. For RPD grading
on CFP, the j value was 0.72. For NIR imaging, this j value was
0.84. The eyes of each participant were graded and classified
separately, and the eye with the more severe grade was used to
classify the person.
Genotyping and Selection of Genetic Variables
Genomic DNA was extracted from peripheral blood leuko-
cytes. All study participants in the RS-I were genotyped with
the Illumina Infinium II HumanHap550 array or Taqman assays
(Applied Biosystems, Foster City, CA, USA). Study participants
from the RS-II were genotyped with the Illumina Human610-
Quad array. HapMap CEU data (release #22) was used for
imputation. Genetic variables associated with AMD were
selected based on previous publications.23,24
Risk Score Three Continent AMD Consortium
Prediction Model
The Three Continent AMD Consortium (3CC) developed a
validated prediction model including a total risk score based on
31 variables; 26 genetic variants associated with AMD, age, sex,
smoking, BMI, and AMD phenotype.23 The total risk score was
based on the sum of the b coefficients from a Cox proportional
hazard analysis, which included all the selected variables. In
this analysis, we used the total genetic risk score, which is a
variant of the total risk score and has been calculated using
only the b coefficients from the genetic variables of the 3CC
prediction model.
Assessment of Nongenetic Variables
Information on the history of diabetes mellitus, education
level, and cigarette smoking were derived from computerized
TABLE 1. Prevalence per AMD Severity Grade According to the Rotterdam Classification Based on CFP Only Versus CFP and NIR Imaging
Grade Definition
Grading CFP, % Grading CFP þ NIR, %
n ¼ 2774 n ¼ 2774
0 No signs of AMD at all OR hard drusen (<63 lm) only 42.70 42.30
1 Soft distinct drusen (‡63 lm) only OR pigmentary abnormalities only 36.10 35.00
2 SID (‡25 lm)/reticular drusen only OR soft distinct drusen (‡63 lm) AND
pigmentary abnormalities 13.60 14.50
3 SID (‡125 lm)/reticular drusen AND pigmentary abnormalities 5.40 6.00
4 Atrophic, neovascular, or mixed AMD 2.20 2.20
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questionnaires administered during home interviews. Smoking
was categorized in never, past, and current smokers. Blood
pressure, systolic and diastolic, was calculated as the average of
two consecutive measurements, using a random-zero mercury
sphygmomanometer. Hypertension was defined as having a
systolic blood pressure ‡140 mm Hg or a diastolic blood
pressure ‡90 mm Hg or using antihypertensive medication at
baseline. Cholesterol, high-density lipoprotein (HDL), and
triglycerides were measured at baseline by the Central Clinical
Chemical Laboratory of the Erasmus University Medical Center.
A subgroup of measurements was carried out in the laboratory
of the Department of Epidemiology and Biostatistics, Erasmus
University Medical School. BMI was calculated as weight in
kilograms divided by height squared in meters. Waist
circumference and hip circumference were measured in
centimeters.
Statistical Analysis
Prevalence of RPD as a function of age was calculated per
image modality. The prevalence of early AMD based on CFP
diagnosis of AMD lesions was compared with the prevalence of
early AMD based on both NIR and CFP grading.
We investigated the association with demographic, genetic,
and environmental variables using various outcomes: SID
versus no drusen, RPD versus no drusen, and RPD versus
SID. Outcomes were binary and the association was assessed
with logistic regression analysis. Total genetic risk scores were
calculated for each individual using only the genetic variables
from the 3CC prediction model. Risk scores were grouped and
stratified for RPD, SID, and no RPD/SID; strata were compared
using v2 statistic test. Analyses investigating concurrence of
drusen types were eye-based, all other analyses were person-
based. All statistical analyses were performed using SPSS
version 21 (SPSS IBM, New York, NY, USA).
RESULTS
Reticular pseudodrusen were detected in 137 (4.9%) of 2774
study participants, of whom 52 (38.0%) were identified on CFP
and 127 (92.7%) on NIR imaging (numbers do not add up to
100% due to overlap). Reticular pseudodrusen were mostly
present from age 70 years onward (Fig. 1) and were bilaterally
present in 69.3%. Only one person had been diagnosed with
RPD at the age of 64.0 years, and RPD were visible on CFP as
well as on NIR imaging. Frequency of RPD increased per age
category; however, the steep rise in those aged 90þ years was
most pronounced when RPD were diagnosed on NIR imaging.
In the Rotterdam classification system, RPD are part of the
criteria for staging. To investigate how much the improved
detection of RPD by NIR imaging influenced AMD prevalence,
we classified each person by using the two gradings: one solely
based on CFP and the other based on CFP and NIR imaging.
Inclusion of the NIR imaging increased the prevalence of early
AMD (stages 2 and 3) from 19.0% to 20.5% (Table 1).
We then investigated the number and type of other drusen
present in eyes with RPD (n¼232) (Fig. 2, Supplementary Fig.
S1). We performed this analysis for drusen within and outside
the grid. Most eyes with RPD had SID, both within and outside
the grid. These eyes also presented with other types of drusen,
but they were less frequent compared with SID. Of eyes with
RPD, only 14 eyes (6.0% of eyes with RPD) did not have any
type of soft drusen, and 9 eyes (3.9% of eyes with RPD) had no
other type of drusen at all. Of these, the contralateral eye of
two persons had drusen. Only five persons with RPD had no
drusen at all, not even in the contralateral eye.
Table 2 shows the frequency of characteristics between
persons with SID, RPD, and those without SID or RPD. Table 3
shows the associations of these characteristics with SID only,
with RPD, and with RPD versus SID. The odds ratio (OR)
represents the risk for a certain parameter on a drusen type
(RPD or SID) in reference to the other drusen type or to
FIGURE 1. Reticular pseudodrusen detection with CFP and NIR. Frequency of RPD was plotted per age category for the different imaging types:
CFP, NIR, and both imaging types combined. x-axis, age category in years; y-axis, percentages; yrs, years.
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absence of RPD/SID. Both SID and RPD were associated with
age (OR 1.09, 95% confidence interval [CI] 1.06–1.11 and OR
1.21, 95% CI 1.17–1.24), respectively. For SID there was no
association with sex (OR 1.02, 95% CI 0.77–1.34), whereas
occurrence of RPD was strongly associated with female sex
(OR 2.10, 95% CI 1.41–3.13). High-density lipoprotein
cholesterol (OR 1.83, 95% CI 1.30–2.59) and triglycerides
(OR 0.66, 95% CI 0.51–0.86) in serum were both significantly
associated with SID, but not with RPD. No other demographic
or environmental risk factors were significantly associated with
SID or RPD. Table 4 shows the association of RPD and SID with
genetic factors. Genetic variants in the CFH gene (rs1061170,
rs12144939, rs800292), the ARMS2 gene (rs10490924), and
the C2/CFB gene (rs641153) were significantly associated with
both drusen types. A variant in the IER3/DDR1 gene (OR 2.54,
95% CI 1.32–4.86, for rs3130783, GG vs. AA) was associated
only with SID, whereas a variant in the C3 gene (OR 1.61, 95%
CI 1.08–2.40, for rs22130199, CG vs. CC) was associated only
with RPD. Two variants were significantly more associated
with RPD than SID. These included the variant in the ARMS2
gene (OR 2.48, 95% CI 1.001–6.17, for rs10490924, TT vs. GG)
and a variant in the VEGFA gene (OR 2.00, 95% CI 1.05–3.8, for
rs943080, CT vs. CC). Genetic risk score frequencies did not
differ significantly between SID and RPD (P ¼ 0.88, v2 test)
(Supplementary Table S1).
DISCUSSION
In this cross-sectional analysis of a population-based study, we
showed that NIR imaging is superior to traditional CFP in the
detection of RPD. We also found that RPD generally coincide
with soft drusen, and were seldom seen as the only AMD
feature. However, the AMD risk profile of RPD showed
quantitative differences with that of SID. Those with RPD
were more likely to be women, have older age, and carry risk
variants in the C3, ARMS2, and VEGFA genes.
Our study confirms that NIR imaging is preferred over the
use of CFP for detection of RPD.11,13,21,25 Of all persons
diagnosed with RPD, 62.7% were not visible on CFP, only on
NIR. By contrast, 7% of those with RPD were diagnosed on CFP
and failed to be detected on NIR. This implies that multimodal
imaging for complete AMD grading is better than using single
imaging devices. Suzuki et al.26 described three subtypes of
RPD: two were better visualized by NIR imaging, and one, the
ribbon-like subtype, was more easily spotted on CFP. Indeed,
we acknowledge that diagnosis of RPD on CFP is mostly based
FIGURE 2. Frequency of other drusen types in eyes with RPD. Other drusen types coinciding with RPD. Grading based on most severe drusen type,
besides RPD, on CFP, according to the Wisconsin Age-Related Maculopathy Grading. Frequencies of other drusen types were stratified for drusen
presence within and outside the grading grid.
TABLE 2. Frequency of Clinical Parameters Stratified for Drusen Type
Variables
No RPD/SID SID RPD
n ¼ 2416 n ¼ 221 n ¼ 137
Age, y (SD) 75.0 (5.6) 77.8 (6.2) 82.1 (6.2)
Sex, % females 54.6 54.8 71.5
Education, y, %
<12 26.8 23.3 29.1
‡12 73.2 76.7 70.9
Smoking, %
Never 31.2 32.1 37.0
Past 57.0 57.0 48.9
Current 11.9 10.9 14.1
Diabetes mellitus, % 13.0 12.4 13.0
Hypertension, % 86.0 86.8 89.7
Systolic blood pressure,
mm Hg (SD) 152.3 (21.4) 154.0 (21.4) 154.0 (23.7)
Diastolic blood pressure,
mm Hg (SD) 85.2 (11.0) 85.9 (11.1) 85.3 (13.3)
Cholesterol, mM (SD) 5.4 (1.1) 5.4 (0.9) 5.3 (1.1)
HDL cholesterol, mM (SD) 1.5 (0.4) 1.6 (0.4) 1.5 (0.4)
Triglycerides, mM (SD) 1.4 (0.7) 1.3 (0.6) 1.4 (0.8)
BMI, kg/m2 27.5 (4.1) 27.1 (4.1) 27.2 (3.9)
Waist circumference,
cm (SD) 93.7 (12.0) 92.0 (11.7) 91.5 (11.0)
Hip circumference,
cm (SD) 102.9 (8.2) 102.6 (9.3) 102.6 (8.7)
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on recognition of the pattern of this feature. Aside from NIR
and CFP, other image modalities also can reveal RPD, such as
fundus autofluorescence, optical coherence tomography
(OCT), confocal blue reflectance, and indocyanine green
angiography. Whether incorporation of all these methods
further improves detection of RPD is questionable. A recent
study assessed the accuracy of RPD detection using all these
modalities, and found that NIR and OCT have the highest
sensitivity, both 94.6%.9
Using NIR imaging increased our estimate of the overall
prevalence of RPD to 4.9%. All previously reported population
estimates of RPD were based on CFP only, and were therefore
lower; the Beaver Dam Eye Study reported an overall
prevalence of 0.7% in a population aged 45þ years,6 the Blue
Mountain Eye Study reported an overall prevalence of 1.95% in
a population aged 50þ years,12 and the Melbourne Collabora-
tive Cohort Study recently reported an overall prevalence of
0.41% in a population 48 to 86 years of age.4 In our study, RPD
were bilateral in 69% of cases, whereas other population-based
cohorts reported a slightly lower frequency of bilaterality, 51%
to 63%, respectively.4,6,12 The higher rates in our study could
be due to the improved detection of RPD using NIR.
We identified several risk factors for RPD and SID. For RPD,
demographic risk factors were older age and female sex,
factors that have been reported by several studies.6,7,11–13,27
We did not find any statistically significant environmental risk
factors, although the relationship with current smoking was
suggestive. Other studies reported risks of RPD for hyperten-
sion, lower income, lower education, higher BMI, angina
pectoris, HDL cholesterol, and triglycerides, but we and many
others could not confirm these findings.6,7,11–13,21,27 Associa-
tions that showed a preference for SID were increased HDL
cholesterol, and decreased triglycerides. These trends were
observed previously for late AMD, and have not been explained
thus far.20 With respect to AMD risk variants, those in the CFH,
C2/FB, and ARMS2 genes were significantly associated with
both RPD and SID in this study; C3, however, was associated
only with RPD. The lack of association with other risk variants
may be due to our limited statistical power to find minor
associations. Remarkably, ARMS2 appeared to have a strong
predilection for RPD. Homozygous carriers of the ARMS2 risk
variant were twice as likely to have RPD than SID. We did not
find this differential distribution for the CFH or C2/FB risk
variants. Previous reports found stronger associations with
ARMS2 than CFH.27,28 Another gene showing a tendency for
RPD was VEGFA. Although this gene was not significantly
associated with either phenotype, it showed a significant risk
difference between RPD and SID.
Eyes featuring RPD without any type of drusen were rare in
our study. We evaluated the risk profiles of these participants
TABLE 3. Comparison of Clinical Parameters Among Drusen Types
Variables
SID vs. No RPD/SID RPD vs. No RPD/SID RPD vs. SID
OR (95% CI) Age and Sex Adjusted OR (95% CI) Age and Sex Adjusted OR (95% CI) Age and Sex Adjusted
Age* 1.09 (1.06–1.11) 1.21 (1.17–1.24) 1.12 (1.07–1.16)
Sex†
Male 1 1 1
Female 1.02 (0.77–1.34) 2.10 (1.41–3.13) 2.16 (1.34–3.49)
Education, y
<12 1 1 1
‡12 1.31 (0.93–1.83) 1.24 (0.82–1.89) 0.90 (0.53–1.52)
Smoking
Never 1 1 1
Past 0.98 (0.70–1.35) 1.06 (0.69–1.62) 0.97 (0.57–1.65)
Current 0.98 (0.60–1.62) 1.77 (0.97–3.23) 1.54 (0.71–3.32)
Diabetes mellitus
No 1 1 1
Yes 0.96 (0.59–1.55) 1.05 (0.57–1.94) 1.41 (0.64–3.09)
Hypertension
No 1 1 1
Yes 0.88 (0.58–1.33) 0.89 (0.49–1.61) 0.91 (0.44–1.89)
Cholesterol, mM 1.06 (0.93–1.21) 0.89 (0.75–1.06) 0.78 (0.61–1.00)
HDL cholesterol, mM 1.83 (1.30–2.59) 1.28 (0.80–2.05) 0.68 (0.39–1.20)
Triglycerides, mM 0.66 (0.51–0.86) 0.95 (0.70–1.28) 1.39 (0.97–1.98)
BMI, kg/m2
25 1 1 1
>25 0.83 (0.61–1.11) 1.13 (0.75–1.70) 1.50 (0.90–2.48)
Waist circumference, cm
 90 1 1 1
> 90 0.82 (0.61–1.11) 1.21 (0.82–1.80) 1.51 (0.93–2.47)
Hip circumference, cm
 100 1 1 1
> 100 0.87 (0.65–1.15) 1.18 (0.81–1.72) 1.29 (0.81–2.06)
* Adjusted for sex.
† Adjusted for age.
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TABLE 4. Genetic Risks Among Drusen Types
Genes
SID vs. No RPD/SID RPD vs. No RPD/SID RPD vs. SID
OR (95% CI) Age and Sex Adjusted OR (95% CI) Age and Sex Adjusted OR (95% CI) Age and Sex Adjusted
CFH (Y402H) rs1061170
TT 1 1 1
CT 1.65 (1.17–2.34) 1.45 (0.95–2.23) 0.91 (0.52–1.58)
CC 3.84 (2.50–5.90) 2.78 (1.57–4.93) 0.83 (0.42–1.66)
CFH rs12144939
GG 1 1 1
GT/TT 0.34 (0.23–0.51) 0.28 (0.17–0.47) 0.89 (0.47–1.71)
CFH rs800292
GG 1 1 1
GA 0.54 (0.39–0.76) 0.55 (0.36–0.84) 0.88 (0.51–1.50)
AA 0.38 (0.17–0.83) 0.30 (0.11–0.87) 0.96 (0.24–3.74)
ARMS2 (A69S) rs10490924
GG 1 1 1
GT 1.81 (1.33–2.47) 2.41 (1.60–3.62) 1.24 (0.75–2.05)
TT 3.25 (1.70–6.20) 7.85 (3.75–16.45) 2.48 (1.001–6.17)
C2/CFB (L9H) rs4151667
TT 1 1 1
TA/AA 0.65 (0.35–1.19) 0.43 (0.17–1.10) 0.78 (0.25–2.44)
C2/CFB (R32Q) rs641153
GG 1 1 1
GA/AA 0.56 (0.34–0.90) 0.38 (0.19–0.75) 0.66 (0.29–1.54)
C3 (R102G) rs2230199
CC 1 1 1
CG 1.19 (0.86–1.64) 1.61 (1.08–2.40) 1.32 (0.80–2.19)
GG 1.28 (0.64–2.56) 1.81 (0.80–4.13) 1.18 (0.41–3.40)
C3 rs433594
GG 1 1 1
GA 0.80 (0.58–1.12) 0.84 (0.55–1.28) 1.16 (0.68–1.96)
AA 0.83 (0.52–1.32) 0.94 (0.51–1.71) 1.01 (0.47–2.16)
CFI rs10033900
CC 1 1 1
CT 1.27 (0.87–1.85) 0.82 (0.52–1.30) 0.68 (0.38–1.24)
TT 1.33 (0.86–2.06) 0.90 (0.52–1.54) 0.62 (0.31–1.24)
LPL rs256
CC 1 1 1
CT/TT 0.88 (0.62–1.25) 0.75 (0.48–1.19) 0.83 (0.46–1.47)
LIPC rs12912415
AA 1 1 1
AG/GG 0.90 (0.64–1.26) 0.75 (0.48–1.17) 0.98 (0.56–1.71)
MYRIP rs2679798
AA 1 1 1
AG 1.04 (0.73–1.49) 1.42 (0.88–2.27) 1.34 (0.75–2.42)
GG 1.23 (0.81–1.87) 1.36 (0.77–2.39) 1.22 (0.61–2.47)
SKIV2L rs429608
GG 1 1 1
GA/AA 0.57 (0.38–0.84) 0.55 (0.33–0.91) 1.01 (0.53–1.92)
ABAC1 rs1883025
CC 1 1 1
CT 0.78 (0.56–1.09) 1.00 (0.67–1.50) 1.03 (0.61–1.74)
TT 1.09 (0.61–1.94) 0.53 (0.19–1.53) 0.38 (0.11–1.28)
CETP rs3764261
CC 1 1 1
CA 1.27 (0.92–1.76) 1.15 (0.76–1.73) 1.06 (0.63–1.79)
AA 1.40 (0.84–2.32) 1.02 (0.50–2.07) 0.68 (0.29–1.63)
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(n ¼ 5), and these were not remarkably different from the
entire group of RPD (Tables 2, 3). Noteworthy, none of the
RPD in these participants were observed on CFP, only on NIR
imaging. Reticular pseudodrusen without any type of drusen
may represent other phenotypes than AMD; in literature, RPD
have been reported to accompany Sorsby fundus dystrophy,
pseudoxanthoma elasticum, acquired vitelliform lesions, and
systemic disorders, such as vitamin A deficiency, cardiovascular
disease, and complement-mediated IgA nephropathy.28–33 In
our study, these five patients showed no other retinal
pathology aside from RPD. A focus on unravelling the etiology
of isolated RPD may help shed light on overarching molecular
mechanisms in retinal disease.
Current insights into RPD pathogenesis are still highly
limited, but a vascular etiology has been suggested.27,28 The
genetic predilections in our study may point toward this
hypothesis. ARMS2 was found to be expressed in the ellipsoid
layer of the photoreceptors and in the intercapillary pillars of
the choroid.34,35 The first is close to the location of RPD,34 and
the latter may help explain the vascular hypothesis.35 Another
hint in this direction is the higher susceptibility of VEGFA and
ARMS2 for neovascular AMD,24 although RPD do not
preferentially accompany this AMD subtype.4,6,7,36 Further-
TABLE 4. Continued
Genes
SID vs. No RPD/SID RPD vs. No RPD/SID RPD vs. SID
OR (95% CI) Age and Sex Adjusted OR (95% CI) Age and Sex Adjusted OR (95% CI) Age and Sex Adjusted
TIMP3 rs5749482
GG 1 1 1
CG/CC 0.87 (0.60–1.27) 0.62 (0.37–1.04) 1.17 (0.40–3.40)
VEGFA rs943080
CC 1 1 1
TC 0.81 (0.56–1.17) 1.34 (0.79–2.24) 2.00 (1.05–3.81)
TT 1.09 (0.72–1.65) 1.51 (0.84–2.73) 1.50 (0.73–3.08)
COL8A1 rs13081855
GG 1 1 1
GT/TT 1.15 (0.78–1.68) 0.90 (0.53–1.52) 0.85 (0.45–1.59)
TNFRSF10A rs13278062
TT 1 1 1
GT 0.92 (0.65–1.30) 0.73 (0.46–1.14) 0.89 (0.51–1.57)
GG 0.72 (0.46–1.12) 0.77 (0.45–1.31) 1.11 (0.57–2.18)
FRK/COL10A1 rs3812111
TT 1 1 1
AT 0.93 (0.68–1.29) 0.92 (0.61–1.39) 0.96 (0.57–1.60)
AA 0.86 (0.52–1.44) 0.53 (0.24–1.15) 0.71 (0.28–1.79)
SLC16A8 rs8135665
CC 1 1 1
CT 1.17 (0.85–1.61) 0.83 (0.54–1.28) 0.73 (0.43–1.24)
TT 1.31 (0.61–2.82) 0.74 (0.21–2.63) 0.74 (0.17–3.18)
ADAMTS9 rs6795735
CC 1 1 1
TC 0.96 (0.68–1.36) 1.03 (0.66–1.61) 1.10 (0.63–1.92)
TT 1.34 (0.88–2.06) 1.35 (0.77–2.37) 0.90 (0.45–1.80)
TGFBR1 rs334353
TT 1 1 1
GT 0.92 (0.66–1.27) 1.09 (0.72–1.64) 1.29 (0.76–2.18)
GG 1.03 (0.55–1.94) 0.62 (0.24–1.63) 0.61 (0.20–1.87)
RAD51B rs8017304
AA 1 1 1
AG 0.82 (0.59–1.13) 0.85 (0.56–1.29) 1.26 (0.74–2.14)
GG 0.63 (0.38–1.03) 0.85 (0.46–1.56) 1.46 (0.67–3.19)
IER3/DDR1 rs3130783
AA 1 1 1
AG 0.85 (0.61–1.19) 0.83 (0.54–1.28) 0.95 (0.55–1.64)
GG 2.54 (1.32–4.86) 1.48 (0.49–4.51) 0.34 (0.10–1.20)
B3GALTL rs9542236
TT 1 1 1
CT 0.77 (0.55–1.09) 1.11 (0.70–1.74) 1.57 (0.89–2.76)
CC 0.92 (0.60–1.39) 1.02 (0.58–1.83) 1.49 (0.73–3.04)
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more, the genes CFH, C3, and VEGFA have been associated
with cardiovascular and coronary artery disease.27,28 Morpho-
logic changes in eyes with RPD suggest that these lesions
follow the pattern of the watershed zones of the choroid, and
correspond with local thinning of this layer.37 Spaide38 found
that choroidal thinning is even more pronounced when RPD
regress and photoreceptors shorten. A recent study of retinal
imaging with adaptive optics showed that photoreceptor
changes precede RPD regression.39 Several histopathologic
studies have studied the molecular content of RPD and SID and
found significant overlap: both contain unesterified cholester-
ol, complement factor H, apolipoprotein E, and vitronec-
tin.16,40 There are also remarkable differences: RPD lack
immunoreactivity for photoreceptors, Mu¨ller cells, and RPE
marker proteins, and have only low concentrations of esterified
cholesterol and other neutral lipids.16,40 Why the deposit in
RPD is located above rather than below the RPE cell is unclear.
Several hypotheses have been made. Rudolf et al.41 suggested
that loss of RPE cell polarity may lead to deposition of
unphagocytized photoreceptor outer segments above rather
than below the RPE cell. Curcio et al.16 suggest that
perturbation of cholesterol homeostasis and the lipid transfer
between the RPE cell and the photoreceptor cell in the context
of an outer retinal lipid-recycling program, could explain the
formation of these deposits. Another hypothesis may be that
shortening of the RPE villi42 jeopardize close contact with
photoreceptor outer segments, and may hamper uptake of
shed discs from the photoreceptor by the RPE cell. In AMD, the
formation of RPD appears to follow that of soft drusen, because
the concurrence of these lesions carries a higher risk of
progression to late AMD.4,6,20 How the associated genes, the
choroidal anatomic changes, and formation of drusenoid
material above the RPE are related remains an intriguing
question for future studies.
To our knowledge, this is the first population-based study
studying RPD using another imaging device aside from CFP.
Other strengths include the large sample size of unselected
persons, the study of RPD within the context of other early
AMD features, and the comparison of risk profiles of RPD
versus SID. Other reports did not specify the frequency of
concurrent AMD lesions in eyes with RPD. Furthermore, we
analyzed a much more comprehensive set of demographic,
environmental, and genetic risk factors for RPD than previous
population-based and clinical studies, which led to new
insights into the genetic background of RPD. A limitation of
our study is the lack of follow-up data with NIR imaging,
hampering the study of RPD incidence and progression. This
needs to be addressed in prospective studies.
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